COMBINATION DRUG THERAPIES WITH THE NOVEL RNA POLYMERASE I INHIBITOR CX-5461 IMPROVE EFFICACY IN THE TREATMENT OF MULTIPLE MYELOMA

被引：0
|
作者：
Maclachlan, K. [1 ,2 ]
Cuddihy, A. [1 ]
Hein, N. [3 ]
Harrison, S. [2 ]
Hannan, R. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Peter MacCallum Canc Ctr, Res Div, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[3] Australian Natl Univ, Dept Canc Biol & Therapeut, Canberra, ACT, Australia
[4] Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic, Australia
[5] Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic, Australia
[6] Peter MacCallum Canc Ctr, Div Canc Med, Melbourne, Vic, Australia
[7] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1240
引用
收藏
页码：512 / 512
页数：1
相关论文
共 50 条
  • [31] The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer
    Yan, Shunfei
    Xuan, Jiachen
    Brajanovski, Natalie
    Tancock, Madeleine R. C.
    Madhamshettiwar, Piyush B.
    Simpson, Kaylene J.
    Ellis, Sarah
    Kang, Jian
    Cullinane, Carleen
    Sheppard, Karen E.
    Hannan, Katherine M.
    Hannan, Ross D.
    Sanij, Elaine
    Pearson, Richard B.
    Chan, Keefe T.
    BRITISH JOURNAL OF CANCER, 2021, 124 (03) : 616 - 627
  • [32] Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma: Current Phase I/II Combinations
    Richardson, Paul
    Laubach, Jacob
    Schlossman, Robert
    Ghobrial, Irene
    Mitsiades, Constantine
    Hideshima, Teru
    Chauhan, Dharminder
    Raje, Noopur
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S40 - S42
  • [33] Inhibition of RNA Polymerase I Transcription by CX-5461 As a Therapeutic Strategy for the Cancer-Specific Activation of p53 in MLL-Rearranged Acute Myeloid Leukemias
    Hein, Nadine
    Bywater, Megan J.
    Stanley, Kim
    Verbrugge, Inge
    Cullinane, Carlene
    Baker, Adele
    Zuber, Hannes
    Rappaport, Amy
    Drygin, Denis
    Huser, Nanni
    Bliesath, Josh
    Ryckman, David M.
    Rice, William G.
    Lowe, Scott W.
    Johnstone, Ricky W.
    Pearson, Richard B.
    McArthur, Grant A.
    Hannan, Ross D.
    BLOOD, 2011, 118 (21) : 673 - 673
  • [34] Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies
    Morgan, Gareth
    BLOOD REVIEWS, 2010, 24 : S27 - S32
  • [35] Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings
    Richardson, Paul G.
    Laubach, Jacob
    Mitsiades, Constantine S.
    Schlossman, Robert
    Hideshima, Teru
    Redman, Katherine
    Chauhan, Dharminder
    Ghobrial, Irene M.
    Munshi, Nikhil
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 154 (06) : 755 - 762
  • [36] Identifying statins and dipyridamole as a novel drug combination showing efficacy in multiple myeloma and acute myelogenous leukemia
    Pandyra, A.
    Sharmeen, S.
    Simpson, C.
    Boutros, P.
    Schimmer, A. D.
    Penn, L. Z.
    EJC SUPPLEMENTS, 2010, 8 (07): : 34 - 35
  • [37] The Efficacy and Safety Analysis of the Bendamustine, Pomalidomide, and Dexamethasone (BPD) Combination Treatment for Patients with Proteasome Inhibitor Intolerance and/or Relapsed Multiple Myeloma
    Zhao, Yiming
    Tian, Wanlu
    Jin, Fengbo
    Jiang, Lei
    Zhang, Rui
    Qian, Wei
    Xia, Leiming
    Yang, Mingzhen
    CURRENT PROTEOMICS, 2024,
  • [38] Safety and efficacy of the combination of bortezomib with the deacetylase inhibitor romidepsin in patients with relapsed or refractary multiple myeloma: Preliminary results of a phase I trial
    Prince, Miles
    Quach, Hang
    Neeson, Paul
    Keegan, Mitch
    Copeman, Michael
    Peinert, Stefan
    Bishton, Mark
    Wolf, Max
    Ritchie, David
    Seymour, John F.
    Carney, Dennis
    Westerman, David
    Harrison, Simon
    BLOOD, 2007, 110 (11) : 353A - 354A
  • [39] Safety and efficacy of the combination of bortezomib and dexamethasone with the deacetylase inhibitor romidepsin in patients with relapsed and refractory multiple myeloma: preliminary results of a phase I trial
    Prince, H. M.
    Quach, H.
    Yuen, K.
    Keegan, M.
    Copeman, M.
    Peinert, S.
    Bishton, M.
    Wolf, M.
    Westerman, D.
    Ritchie, D.
    Seymour, J. F.
    Carney, D.
    Harrison, S. J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 33 - 33
  • [40] A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Gonsalves, Wilson, I
    Neparidze, Natalia
    Allred, Jacob B.
    Kumar, Shaji K.
    Reid, Joel M.
    Shapiro, Geoffrey
    Costello, Brian A.
    Piekarz, Richard
    Baz, Rachid C.
    Devarakonda, Srinivas
    BLOOD, 2022, 140 : 7315 - 7316
12345